Tigecycline Dosing for Perforation Peritonitis
For empirical treatment of perforation peritonitis, administer tigecycline as a 100 mg intravenous loading dose, followed by 50 mg intravenously every 12 hours. This is the FDA-approved dosing regimen for complicated intra-abdominal infections, which includes perforation peritonitis 1.
Standard Dosing Regimen
The dosing is straightforward and applies to most patients:
- Loading dose: 100 mg IV
- Maintenance dose: 50 mg IV every 12 hours
- Infusion time: 30-60 minutes per dose
- Duration: 4-7 days if adequate source control is achieved 2
This regimen is supported by both FDA labeling 1 and international guidelines 3, which specifically list tigecycline at this dose for complicated intra-abdominal infections including peritonitis.
When to Use Tigecycline
Tigecycline should be reserved as a second-line option, primarily for patients with documented beta-lactam allergy 2. The 2024 Italian guidelines specifically recommend:
- First-line: Piperacillin/tazobactam for adequate source control
- Beta-lactam allergy: Eravacycline 1 mg/kg q12h OR Tigecycline 100 mg loading dose then 50 mg q12h 2
Critical caveat: The FDA black box warning states that tigecycline carries an increased all-cause mortality risk (0.6% absolute increase, 95% CI 0.1-1.2%) compared to other antibiotics 1. Use only when alternative treatments are not suitable.
Special Populations Requiring Dose Adjustment
Severe Hepatic Impairment (Child-Pugh C)
- Loading dose: 100 mg IV
- Maintenance dose: 25 mg IV every 12 hours (reduced from standard 50 mg)
- Monitor closely for treatment response 1
Normal Hepatic and Renal Function
- No dose adjustment needed
- Standard dosing applies even in patients on CRRT, as tigecycline clearance is minimally affected 4
Duration of Therapy
Treat for 4 days in immunocompetent, non-critically ill patients if adequate source control is achieved 2.
Extend to 7 days for:
- Critically ill patients
- Immunocompromised patients
- Inadequate or delayed source control
- Persistent signs of infection 2, 3
If signs of infection persist beyond 7 days, diagnostic investigation is warranted rather than simply continuing antibiotics 2.
Clinical Efficacy Data
Tigecycline demonstrated clinical cure rates of 80-91% in complicated intra-abdominal infections including perforation peritonitis, comparable to imipenem/cilastatin 1, 5, 6. The drug covers the polymicrobial flora typical of peritonitis, including:
- Gram-negative aerobes (E. coli, Klebsiella, Enterobacter)
- Gram-positive organisms (including MRSA)
- Anaerobes (Bacteroides fragilis, Clostridium perfringens) 1
Important limitation: Tigecycline has poor activity against Pseudomonas aeruginosa 7. If Pseudomonas is suspected or isolated, switch to an anti-pseudomonal agent.
Common Pitfalls to Avoid
Do not use tigecycline as first-line therapy - Reserve for beta-lactam allergies or resistant organisms given the mortality signal 1
Do not underdose the loading dose - The 100 mg loading dose is essential for rapid therapeutic levels 1
Anticipate gastrointestinal side effects - Nausea (24-31%) and vomiting (19-26%) are common; consider prophylactic antiemetics 5, 8
Do not use for hospital-acquired or ventilator-associated pneumonia - FDA specifically contraindicates this due to increased mortality 1
Ensure adequate source control - Antibiotics alone are insufficient; surgical intervention or drainage is mandatory for perforation peritonitis 2